Trifluoroacetic acid → 3-(((5-Oxo-1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidin-7-yl)oxy)methyl)benzonitrile

HRID 873186노트

반응식

HRID 873186 반응식
[C:1]([C:3]1[CH:4]=[C:5]([CH:25]=[CH:26][CH:27]=1)[CH2:6][O:7][C:8]1[CH:9]=[C:10]2[N:17](C(OC(C)(C)C)=O)[CH2:16][CH2:15][N:11]2[C:12](=[O:14])[N:13]=1)#[N:2].C(O)(C(F)(F)F)=O>ClCCl>[O:14]=[C:12]1[N:11]2[CH2:15][CH2:16][NH:17][C:10]2=[CH:9][C:8]([O:7][CH2:6][C:5]2[CH:4]=[C:3]([CH:27]=[CH:26][CH:25]=2)[C:1]#[N:2])=[N:13]1

참가 물질

4

반응물 2

HCID 6422Trifluoroacetic acidHCID 71241009tert-butyl 7-((3-cyanobenzyl)oxy)-5-oxo-2,3-dihydroimidazo[1,2-c]pyrimidine-1(5H)-carboxylate

생성물 1

HCID 712438273-(((5-Oxo-1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidin-7-yl)oxy)methyl)benzonitrile수율 62.1%

시약·촉매·용매 1

HCID 6344Dichloromethane용매

실험 절차

A solution of tert-butyl 7-((3-cyanobenzyl)oxy)-5-oxo-2,3-dihydroimidazo[1,2-c]pyrim-idine-1(5H)-carboxylate (20 mg, 0.054 mmol) in dichloromethane (DCM) (4 mL) was added TFA (0.5 mL, 6.49 mmol) at room temperature. The reaction mixture was stirred at rt overnight, then concentrated to remove solvent, diluted with sat. NaHCO3 (5 mL) solution and EtOAc (15 mL). Separated organic part was dried over Na2SO4, filtered and concentrated. Purification via MDAP (Gilson GX-281, mobile phase: 0.01% NH4HCO3, CH3CN/water, 50˜95%) afforded the title product (9 mg) as a white solid.

후처리

  1. concentrationconcentrated
  2. customto remove solvent
  3. additiondiluted with sat. NaHCO3 (5 mL) solution and EtOAc (15 mL)
  4. dry with materialSeparated organic part was dried over Na2SO4
  5. filtrationfiltered
  6. concentrationconcentrated
  7. customPurification via MDAP (Gilson GX-281, mobile phase: 0.01% NH4HCO3, CH3CN/water, 50˜95%)

출처 및 근거

ORD 기록
ord-c529647aa5704663a5cb117a65b5e3ba
출처 데이터셋
uspto-grants-2015_03
특허 번호
US08975400B2

반응 노트

불러오는 중…